571 results match your criteria g-csf amd3100

Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation.

Cells 2021 Apr 30;10(5). Epub 2021 Apr 30.

Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

In the context of hematopoietic stem cell (HSC) transplantation, conditioning with myelo- and immune-ablative agents is used to eradicate the patient's diseased cells, generate space in the marrow and suppress immune reactions prior to the infusion of donor HSCs. While conditioning is required for effective and long-lasting HSC engraftment, currently used regimens are also associated with short and long-term side effects on extramedullary tissues and even mortality. Particularly in patients with severe combined immunodeficiency (SCID), who are generally less than 1-year old at the time of transplantation and often suffer from existing comorbidities. Read More

View Article and Full-Text PDF

Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.

Curr Oncol 2021 Apr 22;28(3):1571-1580. Epub 2021 Apr 22.

College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.

Granulocyte colony-stimulating factor (G-CSF) is the first line treatment for mobilization, most commonly using a regimen of daily filgrastim. The use of biosimilars can provide substantial cost savings to the health care system while delivering comparable efficacy outcomes. In 2016, the Saskatchewan Cancer Agency was a leader in Canada, instituting formulary changed from a G-CSF originator product to a cost savings alternative biosimilar for stem cell mobilization prior to autologous stem cell transplant (ASCT) and for engraftment. Read More

View Article and Full-Text PDF

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.

Transplant Cell Ther 2021 Apr 26. Epub 2021 Apr 26.

Stanford Cancer Institute; Division of Blood and Marrow Transplantation-and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA. Electronic address:

Growth factor and chemotherapy-based stem cell mobilization strategies are commonly used for patients with multiple myeloma. We retrospectively compared 398 patients mobilized between 2017-2020 using either cyclophosphamide (4g/m) plus granulocyte colony stimulating factor (GCSF) or G-CSF alone, with on demand plerixafor (PXF) in both groups. While total CD34 yield was higher after chemo-mobilization compared to GCSF+/-PXF (median 13. Read More

View Article and Full-Text PDF

Inhibition of SGLT-2 rescues bone marrow cell traffic for vascular repair. Role of glucose control and ketogenesis.

Diabetes 2021 Apr 26. Epub 2021 Apr 26.

Department of Medicine, University of Padova, 35128 Padua, Italy

The mechanisms whereby sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in people with diabetes are incompletely understood. Recent studies show that SGLT2i may increase the levels of circulating cells with vascular regenerative capacity, at least in part by lowering glycemia. Here, we used mice with streptozotocin-induced diabetes treated with the SGLT2i dapagliflozin at a dose that reduced glucose levels by ∼20%. Read More

View Article and Full-Text PDF

Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.

Transplant Cell Ther 2021 Mar 28;27(3):244.e1-244.e8. Epub 2021 Jan 28.

Hematology Unit, Romagna Transplant Center, Hospital of Ravenna, Ravenna, Italy. Electronic address:

The optimal stem cell (SC) mobilization strategy for patients with multiple myeloma (MM) remains a matter of debate. Possible approaches include low or high doses of cyclophosphamide (Cy), other chemotherapeutic agents, or granulocyte colony-stimulating factor (G-CSF) alone. The scope of the study was to compare low-dose Cy plus G-CSF versus intermediate-high-dose Cy plus G-CSF versus G-CSF alone for SC mobilization in MM, in terms of efficacy and safety. Read More

View Article and Full-Text PDF

Mobilization of endothelial progenitor cells promotes angiogenesis after full thickness excision by AMD3100 combined with G-CSF in diabetic mice by SDF-1/CXCR4 axis.

Diab Vasc Dis Res 2021 Mar-Apr;18(2):14791641211002473

Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.

Aim: The aim of the present study was to investigate the effect of the mobilization of EPCs by AMD3100 combined with G-CSF on wound healing in diabetic mice.

Methods: The full-thickness excisional wounds model of diabetic mice (db/db) was examined by hematoxylin and eosin staining, immunohistochemical staining, and western blotting to compare the wound healing and neovascularization among the combination, AMD3100 alone, G-CSF alone, and control groups.

Results: The wounds reached the complete closure in the combination, AMD3100 alone, G-CSF alone, and control groups on days 17, 20, 21, 21 after surgery, respectively. Read More

View Article and Full-Text PDF

The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice.

Stem Cell Res Ther 2021 Mar 24;12(1):209. Epub 2021 Mar 24.

Tongji Shanxi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Taiyuan, 030032, China.

Background: Several studies have confirmed that mobilizing bone marrow-derived stem cells (BMSCs) ameliorates renal function loss following cisplatin-induced acute kidney injury (AKI). The aim of this study was to explore whether the combination of granulocyte-colony stimulating factor (G-CSF) and plerixafor (AMD3100) exerts beneficial effects on renal function recovery in a model of cisplatin-induced nephrotoxicity.

Methods: C57BL/6J mice received intraperitoneal injections of G-CSF (200 μg/kg/day) for 5 consecutive days. Read More

View Article and Full-Text PDF

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.

Bone Marrow Transplant 2021 Mar 22. Epub 2021 Mar 22.

Department of Cellular Therapy and Transfusion Medicine, Careggi University Hospital, Florence, Italy.

Given the availability and efficacy of the mobilizing agent plerixafor in augmenting hematopoietic progenitor cell mobilization with granulocyte colony-stimulating factor (G-CSF), there is a strong case for comparing the cost-effectiveness of mobilization with G-CSF + cyclophosphamide versus G-CSF alone. This study investigated the cost and effectiveness (i.e. Read More

View Article and Full-Text PDF

Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation.

J Clin Apher 2021 Mar 12. Epub 2021 Mar 12.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA.

Administration of plerixafor with granulocyte-colony stimulating factor (G-CSF) mobilizes CD34+ cells much more effectively than G-CSF alone, but cost generally limits plerixafor use to patients at high risk of insufficient CD34+ cell collection based on low peripheral blood (PB) CD34+ counts following 4 days of G-CSF. We analyzed costs associated with administering plerixafor to patients with higher day 4 CD34+ cell counts to decrease apheresis days and explored the use of a fixed split dose of plerixafor instead of weight-based dosing. We analyzed 235 patients with plasma cell disorders or non-Hodgkin's lymphoma who underwent progenitor cell mobilization and autologous hematopoietic cell transplantation (AHCT) between March 2014 and December 2017. Read More

View Article and Full-Text PDF

A simplified CD34+ based preharvest prediction tool for HPC(A) collection.

Transfusion 2021 May 11;61(5):1525-1532. Epub 2021 Mar 11.

Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Background: Hematopoietic stem cell transplantation is an important treatment that is dependent on the collection of sufficient CD34+ hematopoietic progenitor cells. The peripheral blood CD34 count (PB CD34+ counts) measured by flow cytometry can be used in predicting CD34+ stem cell yields hours before the completion of collection. Previously described formulas to predict the yield have used many different variables. Read More

View Article and Full-Text PDF

Plerixafor added to G-CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR-alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G-CSF alone.

J Clin Apher 2021 Mar 8. Epub 2021 Mar 8.

Dmitri Rogachev National Research Centre for Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russian Federation, Moscow, Russia.

Background: Collection of a large number of early hematopoietic progenitors is essential for allogeneic apheresis products intended for TCR-alpha/beta depletion.

Materials And Methods: We added plerixafor 0.24 mg/kg body weight (bw) on day 4 of high-dose filgrastim mobilization 10 hours prior to apheresis in 16 (30. Read More

View Article and Full-Text PDF

[Analysis of the efficacy and safety of plerixafor combined with G-CSF in plasma cell disease mobilization].

Zhonghua Xue Ye Xue Za Zhi 2021 Jan;42(1):21-26

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing 100044, China Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215123, China.

To analyze the effect and safety of plerixafor combined with G-CSF mobilization in plasma cell disease. The clinical baseline data, success rate of collection, and adverse reactions of consecutive cases of plasma cell disease were analyzed retrospectively, where the patients received plerixafor combined with G-CSF for autologous hematopoietic stem cell mobilization in Peking University People's Hospital from January 2018 to December 2019. Forty-nine patients with plasma disease were included, of which 39 (79. Read More

View Article and Full-Text PDF
January 2021

Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice.

Blood Adv 2021 Mar;5(5):1239-1249

Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA.

We have developed an in vivo hemopoietic stem cell (HSC) gene therapy approach without the need for myelosuppressive conditioning and autologous HSC transplantation. It involves HSC mobilization and IV injection of a helper-dependent adenovirus HDAd5/35++ vector system. The current mobilization regimen consists of granulocyte colony-stimulating factor (G-CSF) injections over a 4-day period, followed by the administration of plerixafor/AMD3100. Read More

View Article and Full-Text PDF

Danger-associated molecular pattern molecules take unexpectedly a central stage in Nlrp3 inflammasome-caspase-1-mediated trafficking of hematopoietic stem/progenitor cells.

Leukemia 2021 Feb 23. Epub 2021 Feb 23.

Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.

Like their homing after transplantation to bone marrow (BM), the mobilization of hematopoietic stem/progenitor cells (HSPCs) is still not fully understood, and several overlapping pathways are involved. Several years ago our group proposed that sterile inflammation in the BM microenvironment induced by pro-mobilizing agents is a driving force in this process. In favor of our proposal, both complement cascade (ComC)-deficient and Nlrp3 inflammasome-deficient mice are poor G-CSF and AMD3100 mobilizers. Read More

View Article and Full-Text PDF
February 2021

First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.

Transfus Apher Sci 2021 Feb 12:103070. Epub 2021 Feb 12.

Service d'Hématologie et Thérapie Cellulaire, Établissement Hospitalier Universitaire 1(er) Novembre, faculté de médecine, université d'Ahmed Benbella 1, Oran, Algeria.

Mobilization failure in patients is a major therapeutic concern which makes subsequent ASCT impossible. A new growth factor called Plerixafor (Mozobil®) developed by the pharmaceutical industry (Sanofi-aventis, France), is a chemoreceptor antagonist, CXCR4 type, which disrupts the interaction of SDFI and CXCR4, thereby enhancing the effect of G-CSF mobilization and is especially indicated for mobilization failure. Currently, there is a generic of plerixafor developed by the pharmaceutical industry (Hetero Drugs Ltd, India). Read More

View Article and Full-Text PDF
February 2021

Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.

Transfus Apher Sci 2021 Feb 5:103077. Epub 2021 Feb 5.

Department of Pediatrics Oncology, Children's Memorial Health Institute, Warsaw, Poland, Al. Dzieci Polskich 20, 04-730 Warsaw, Poland. Electronic address:

Failure of autologous peripheral blood CD34 stem cells collection can adversely affect the treatment modality for patients with hematological and nonhematological malignant diseases where high dose chemotherapy followed by hematopoietic stem cell transplantation has become part of their treatment. Plerixafor in conjunction with G-CSF is approved for clinical use as a mobilization agent. The clinical efficacy of Plerixafor in CD34 cells collection was analyzed in our institution. Read More

View Article and Full-Text PDF
February 2021

Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH).

Transfus Apher Sci 2021 Apr 12;60(2):103052. Epub 2021 Jan 12.

Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, ICMHO, Hospital Clínic, IDIBAPS, UB, Barcelona, Spain.

Plerixafor (Mozobil, Sanofi) is approved for using in patients with lymphoma and multiple myeloma when steady-state mobilization strategies fail. Although off-label use of plerixafor in healthy related donors (HRD) is known, limited data are available and no recommendations exist to guide its use in this setting. With the aim of collecting data from HRDs who received plerixafor in our country, we designed an observational case series study within the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH). Read More

View Article and Full-Text PDF

A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.

Leuk Lymphoma 2021 Jan 19:1-14. Epub 2021 Jan 19.

Division of Oncology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA.

Interactions between the bone marrow microenvironment and MDS tumor clones play a role in pathogenesis and response to treatment. We hypothesized G-CSF and plerixafor may enhance sensitivity to azacitidine in MDS. Twenty-eight patients with MDS were treated with plerixafor, G-CSF and azacitidine with a standard 3 + 3 design. Read More

View Article and Full-Text PDF
January 2021

Protein and Small-Molecule Leucopoiesis and Thrombopoiesis Stimulators.

Mini Rev Med Chem 2020 Dec 30. Epub 2020 Dec 30.

Department of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Brno,. Czech Republic.

Pluripotent stem cells of the bone marrow are stimulated by different cytokines to proliferation and differentiation into various types of blood cells. These cytokines are mostly glycoproteins. Erythropoietin stimulates stem cells to the formation of erythrocytes while colony-stimulating factors cause the formation of different types of white blood cells. Read More

View Article and Full-Text PDF
December 2020

[Cost-effectiveness of peripheral blood stem cell collection using plerixafor: a single-center study].

Rinsho Ketsueki 2020 ;61(11):1563-1569

Department of Hematology, Japanese Red Cross Medical Center.

Plerixafor is increasingly used in combination with granulocyte-colony-stimulating factor (G-CSF) for peripheral blood stem cell collection. Although it is an expensive drug, its cost-benefit performance is not well investigated. Thus, we analyzed its cost-effectiveness in our hospital. Read More

View Article and Full-Text PDF
February 2021

Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization.

Blood Rev 2021 May 31;47:100771. Epub 2020 Oct 31.

Department of Medicine, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic address:

Hematopoietic cell transplantation (HCT) has become a primary treatment for many cancers. Nowadays, the primary source of hematopoietic cells is by leukapheresis collection of these cells from peripheral blood, after a forced egress of hematopoietic cells from marrow into blood circulation, a process known as "mobilization". In this process, mobilizing agents disrupt binding interactions between hematopoietic cells and marrow microenvironment to facilitate collection. Read More

View Article and Full-Text PDF

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost.

Leuk Res Rep 2020 30;14:100227. Epub 2020 Oct 30.

SODc Terapie Cellulari e Medicina Trasfusionale, Azienda Ospedaliera Careggi, Firenze, Italy.

In CD34+ cells mobilization of patients with multiple myeloma (MM), the use of Cyclophosphamide (CTX) at a dose of 2 g/m has low efficacy although also lower toxicity. The suboptimal mobilizing effect of low-dose CTX, however, may be overcome by plerixafor (PLX) on demand. We conducted a prospective multicenter study in 138 patients with MM to evaluate CTX 2 g/m in association with granulocyte-colony stimulating factor (G-CSF) and on-demand PLX. Read More

View Article and Full-Text PDF
October 2020

Plerixafor-based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better CD34 collection yield: A retrospective analysis.

J Clin Apher 2021 Feb 20;36(1):78-86. Epub 2020 Oct 20.

Hematology y Hemotherapy Unit, Hematología y Oncología Pediátricas, Fundación para la Investigación Biomédica Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

Introduction: In order to propose risk-adapted mobilization algorithms, several authors have tried to look for predictive factors of the CD34 yield in healthy pediatric donors. Donor recipient body weight ratio (D/R ratio) was identified as one of the main variables related with the success to achieve the target cell dose for transplantation. According to this variable we modified the mobilization schedule. Read More

View Article and Full-Text PDF
February 2021

Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) - a focus on healthcare resource utilization and cost.

Int J Hematol 2021 Feb 15;113(2):271-278. Epub 2020 Oct 15.

Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

This study explored the burden associated with stem cell mobilization, with or without cyclophosphamide (CPA), in patients who intended to receive autologous stem cell transplantation (ASCT) for multiple myeloma (MM). A Japanese health care claims database (MDV) was used to analyze the health care resource utilization patterns and medical cost between 2013 and 2016 (pre-plerixafor launch). The patients were further categorized into groups who received granulocyte-colony stimulating factor (G-CSF) alone or G-CSF + CPA group and analyzed in both mobilization and ASCT phases of treatment. Read More

View Article and Full-Text PDF
February 2021

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial.

Bone Marrow Transplant 2021 Mar 7;56(3):635-645. Epub 2020 Oct 7.

Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU, Dresden, Germany.

We conducted a prospective clinical trial to investigate the safety and efficacy of plerixafor (P) in allogeneic peripheral blood stem cells (PBSC) donors with poor mobilization response to standard-dose granulocyte colony-stimulating factor (G-CSF), defined by <2 × 10 CD34 + cells/kg recipient body-weight (CD34+/kg RBW) after 1st apheresis. A single dose of 240 µg/kg P was injected subcutaneously at 10 p.m. Read More

View Article and Full-Text PDF

Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.

Bone Marrow Transplant 2021 02 15;56(2):492-504. Epub 2020 Sep 15.

Center for Bone Marrow Transplant and Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India.

Allogenic hematopoietic stem cell transplant is the only curative option for symptomatic sickle cell disease (SCD). HLA haploidentical related donor transplants are associated with high graft failure rates. We conceptualized a novel protocol (APOLLO protocol) using pre-transplant immune and myelosuppression (PTIS) using fludarabine, cyclophosphamide, and dexamethasone followed by augmented John Hopkins protocol by adding thiotepa to conditioning. Read More

View Article and Full-Text PDF
February 2021

Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma.

Int J Hematol 2020 Dec 2;112(6):835-840. Epub 2020 Sep 2.

Department of Medical Oncology, CRC, ACTREC, Tata Memorial Centre, 3rd floor, Paymaster Shodhika, Navi Mumbai, Maharashtra, 410210, India.

Hematopoietic stem and progenitor cell (HSPC) mobilization regimens in multiple myeloma typically use filgrastim (GCSF) alone or combination of GCSF with plerixafor or high-dose cyclophosphamide. Murine model and human studies have shown HSPC mobilization potential of bortezomib. A total of 37 patients underwent mobilization using bortezomib 1. Read More

View Article and Full-Text PDF
December 2020

Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience.

Bone Marrow Transplant 2021 02 14;56(2):395-399. Epub 2020 Aug 14.

Service d'Hématologie Clinique, Hotel Dieu, Nantes, France.

Triplet-drug regimen bortezomib-thalidomide-dexamethasone (VTD) and bortezomib-lenalidomide-dexamethasone (VRD) are considered as standard of care induction prior autologous stem-cell transplantation (ASCT) in myeloma. In addition to improve response rate, induction therapy should preserve an adequate stem-cell collection. In the present retrospective study, we analyzed stem-cell collection in 325 newly diagnosed myeloma patients who received either VTD or VRD induction before ASCT. Read More

View Article and Full-Text PDF
February 2021